Patterns of platinum drug use in an acute care setting: a retrospective study
Platinum drugs have been in use in cancer treatment for more than 40 years, but little is known about the pattern of their use. The aim of this study was to examine the patterns of platinum drug use, with a secondary aim to describe the occurrence of dose reductions.
A retrospective analysis was conducted of oncology pharmacy dispensing records from a single hospital in Australia. Data related to drug choice, regimen and dose reductions were included in this study if the patient had received their last round of chemotherapy between November 2014 and July 2015.
Of the 156 patients included in the study, 46% were dispensed a platinum drug during their treatment. The most commonly dispensed drugs were cisplatin (40%), carboplatin (40%) and oxaliplatin (15%), while some patients (5%) received more than one platinum drug. Dose reductions were more common in patients who were treated with a platinum drug (73%) compared with patients treated with non-platinum drugs (55%). The most common reason for a dose reduction was cytopenia.
The findings suggest that platinum drugs remain one of the most commonly dispensed drugs to treat cancer patients and most patients receive a dose reduction during treatment.
KeywordsPlatinum drugs Cancer Chemotherapy Prescribing Dose reductions
Concord Repatriation General Hospital
Epidermal growth factor receptor
Non-small cell lung cancer
The authors wish to thank Rosemary Burke, Director of Pharmacy, CRGH, Robert Bayley, Oncology Pharmacy Department Manager, CRGH, and the rest of the Oncology Pharmacy Department at CRGH for graciously accommodating the researcher during the data collection phase and Professor Ines Krass, University of Sydney, Faculty of Pharmacy, for her assistance with statistical analysis.
Compliance with ethical standards
Conflict of interest
Author A declares that he/she has no conflict of interest. Author B declares that he/she has no conflict of interest. Author C declares that he/she has no conflict of interest. Author D declares that he/she has no conflict of interest. Author E declares that he/she has no conflict of interest. Author F declares that he/she has no conflict of interest. Author G declares that he/she has no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Sydney Local Health District Concord Hospital Human Research Ethics Committee (HREC Reference Number: LNR/17/CRGH/196).
- Australian Institute of Health and Welfare (2017) Cancer in Australia 2017. Cancer series. Australian Institute of Health and Welfare, CanberraGoogle Scholar
- Bosl GJ, Bajorin DF, Sheinfeld J, Motzer RJ, Chaganti RS (2001) Cancer of the testis. Cancer principles practice of oncology, 6th edn. Lippincott Williams and Wilkins, Philadelphia, 1491–1518Google Scholar
- Cancer Institute NSW (2011) eviQ cancer treatments onlineGoogle Scholar
- Greystoke A, Steele N, Arkenau H-T, Blackhall F, Haris NM, Lindsay CR, Raffaele C, Voskoboynik M, Summers Y, So K, Ghiorghiu D, Dymond AW, Hossack S, Plummer R, Dean E (2017) SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. Br J Cancer 117:938–946CrossRefPubMedPubMedCentralGoogle Scholar
- Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T (1996) Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute’s anticancer drug screen panel. Biochem Pharmacol 52(12):1855–1865CrossRefPubMedGoogle Scholar
- Stewart B, Wild CP (2014) World Cancer Report 2014: World Health Organization, GenevaGoogle Scholar
- Sweetman S (2017) Martindale: the complete drug reference. Pharmaceutical Press, LondonGoogle Scholar
- Vijayvergia N, Li T, Wong Y-N, Hall MJ, Cohen SJ, Dotan E (2016) Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer: chemotherapy adoption in older patients with CRC. Cancer 122(20):3191–3198CrossRefPubMedPubMedCentralGoogle Scholar
- Yanagimoto Y, Takiguchi S, Miyazaki Y, Makino T, Takahashi T, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Hosoda H, Kangawa K, Mori M, Doki Y (2016) Improvement of cisplatin-related renal dysfunction by synthetic ghrelin: a prospective randomised phase II trial. Brit J Cancer 114:1318–1325CrossRefPubMedGoogle Scholar
- Yang CH, Fukuoka M, Mok TS, Wu YL, Thongprasert S, Saijo N, Chu DT, Jiang H, Duffield EL, Ichinose Y (2010) Final overall survival (OS) results from a Phase III, randomised, open-label, first-line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small cell lung cancer (NSCLC) in Asia. Ann Oncol 21:1–2CrossRefGoogle Scholar